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MiceAbstract The current study was carried out to investigate the protective role of biotin in kidney
injury and oxidative stress in diabetic mice type 1. Male Swiss albino mice were randomly divided
into 3 groups. Control group received saline. Diabetes type 1 was induced in second and third
groups by intraperitoneal injection of streptozotocin as a single dose (150 mg/kg). Second group
remained as the untreated diabetic group and the third group received 15 mg/kg daily oral dose
of biotin for 12 successive days. Biochemical results showed signiﬁcant elevation in blood glucose
and urea levels in both diabetic groups. Also, there is an increase in glomerular areas and
decrease in glomerular cellularity in both diabetic groups. Histopathological results showed severe
alterations in the untreated diabetic group represented by distorted glomeruli, inﬂammatory cells,
and giant macrophages. In addition, there was an intense immune-reaction response toward
acrolein indicator of oxidative damage. Upon biotin administration of diabetic mice, the above
mentioned histopathological changes were reduced and also acroline reaction of oxidative damage
was diminished. Our ﬁndings prove that biotin has a protective role against streptozotocin-induced
oxidative damage in kidneys of laboratory mice.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus is the most common metabolic disorder. It is
characterized by hyperglycemia that results from an absolute
or relative insulin deﬁciency and is associated with long-term
complications affecting the eyes, kidneys, heart and nerves
(Gispen and Biessels, 2000). Diabetes mellitus is classiﬁed into
two types, insulin dependent diabetes mellitus (IDDM, type 1)
and non-insulin-dependent diabetes mellitus (NIDDM, type
2). Type I diabetes is an autoimmune disease characterized
by a local inﬂammatory reaction in and around islets that is
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Type II diabetes is characterized by peripheral insulin resis-
tance and impaired insulin secretion (Foulis, 1987; Arora
et al., 2009). The prevalence of diabetes for all age-groups
worldwide was estimated to be 2.8% in 2000 and 4.4% in
2030. The total number of people with diabetes is projected
to rise from 171 million in 2000 to 366 million in 2030 (Wild
et al., 2003). In spite of the introduction of hypoglycemic
drugs, diabetes and related complications continue to be a
major medical problem (Nammi et al., 2003). The chronic
hyperglycemia was found to increase the production of free
radicals that is associated with long-term damage, dysfunction,
and failure of various organs, especially the eyes, kidneys,
nerves, heart, and blood vessels (Mohamed et al., 1999;
Baynes, 1991).
Diabetic nephropathy is a major cause of end-stage renal
failure worldwide, with a prevalence expected to double over
the next decade (Locatelli et al., 2003). Type 2 diabetes
accounts for 90% of patients with diabetic nephropathy.
Despite conventional therapies of glycemic and BP control,
many patients still have evidence of renal damage (Svensson
et al., 2003). Kidney macrophage accumulation is known to
play a role in non-diabetic renal injury and the mechanisms
of macrophage accrual are well-established in these diseases
(Nikolic-Paterson and Atkins, 2001). However, diabetic
nephropathy is not generally considered to be an inﬂammatory
disease. This view is currently changing because recent studies
of human biopsy samples and animal models have established
kidney macrophage accumulation as a characteristic of dia-
betic nephropathy (Sassy-Prigent et al., 2000; Chow et al.,
2004). Renal macrophage accumulation correlates with the
severity of glomerular and tubulointerstitial injury in experi-
mental diabetic nephropathy and non-diabetic models of renal
disease (Yang et al., 1998; Lan et al., 1991).
Biotin (Vitamin H) is part of the B complex group of
vitamins. All B vitamins help the body to convert food
(carbohydrates) into fuel (glucose), which is used to produce
energy. These B vitamins, often referred to as B complex
vitamins, also help the body metabolize fats and protein.
B complex vitamins are needed for healthy skin, hair, eyes,
and liver. The body needs biotin to metabolize carbohydrates,
fats, and amino acids (the building blocks of protein). Like all
B vitamins, it is a water-soluble vitamin, meaning the body
does not store it. However, bacteria in the intestine can make
biotin. It is also available in small amounts in a number of
foods. Biotin is also important for normal embryonic growth,
making it a critical nutrient during pregnancy (Said, 2002;
Ba´ez-Saldan˜a et al., 2004; Mock et al., 2002; Fiume, 2001).
The aim of the current work is to investigate whether biotin
can reduce diabetic nephropathy in type 1 diabetic mice and
hence can be advised for diabetic patients to keep kidneys safe
from injury or not.2. Material and methods
2.1. Animals and experimental design
Thirty male Swiss albino mice (25 ± 3 g) were randomly
divided into three groups, ten mice per each group. Mice were
housed in polypropylene cages inside a well-ventilated room at
22 ± 1 C and 12-h periods of light and dark, with free accessto clean water and commercial mice food. All mice were fasted
for 20 h before experimental induction of diabetes. The ﬁrst
group received cold citrate buffer (pH 4.5) and served as con-
trol. Experimental diabetes was induced in the second and
third groups via intraperitoneal injection of a single dose of
150 mg/kg streptozotocin (Sigma Chemicals Co., St. Louis,
MO, USA) dissolved in cold 0.01 M citrate buffer, pH 4.5.
The experiments were approved by state authorities and fol-
lowed Saudi Arabian rules for animal protection. The induced
diabetes was conﬁrmed via colorimetric detection of blood glu-
cose levels after three days of STZ injection in blood collected
from tails of study animals. After three days of induction of
diabetes, animals within the third group received a daily dose
of biotin (15 mg/kg) orally for twelve successive days. At the
end of experimental period, animals were sacriﬁced.
2.2. Kidney index
Each mouse was weighed individually; and both kidneys were
weighed. Finally, the kidney index was calculated by dividing
the kidney weight by the body weight and then multiplying
by 100 and the results were statistically analyzed by SPSS.
2.3. Biochemical analysis
Blood was collected from the heart of animals into heparinized
tubes and plasma was separated by cold centrifugation.
Plasma was assayed for levels of glucose, urea and creatinine
using commercially available kits (Biomerieux, Marcy l’Etoil,
France).
2.4. Histological examination and renal injury
Pieces of kidney were freshly prepared, ﬁxed in 10% neutral
buffered formalin, and then embedded in parafﬁn. Sections
were cut and stained with hematoxylin and eosin.
The stained tissue sections were scanned for renal tissue
abnormalities. Glomerular cellularity was determined by
counting the number of nuclei in 20 hilar glomerular tuft
cross-sections per animal. The glomerular tuft areas were mea-
sured with Motic 200 image analyzer (Hong Kong, China).
2.5. Immunohistochemical localization of acrolein (ABC
method)
Parafﬁn embedded kidney sections were deparafﬁnized in
xylene and rehydrated in descending grades of alcohol and
ﬁnally distilled water. Sections then were heated in citrate buf-
fer (pH 6) within microwave for 5 min. After that sections were
washed with PBS buffer for 5 min and incubated in peroxidase
blocking solution for 10 min. Sections were incubated over-
night at 4 C in diluted primary antibody (anti-acrolein)
(mouse monoclonal antibody ab48501) then incubated in
biotinylated goat anti-mouse (ab128976) as secondary anti-
body for 30 min, followed by incubation in avidin–biotin com-
plex for 30 min, then incubated in DAB (ab64238) as
chromogenic substrate for ten minutes. The stained sections
were counter stained with Mayer’s hematoxylin, and dehy-
drated within ascending grades of alcohol and cleared with
two changes of xylene, mounted with cover slip based on
DPX mountant. All reagents were purchased from Abcam
566 B.A. Aldahmash et al.company (Cambridge, UK). Kidney sections were examined
under microscope for brown immunoreactivity color and pho-
tos at magniﬁcation of 200·.
2.6. Statistical analysis
One-way ANOVA was carried out, and the statistical compar-
isons among the groups were performed with Duncan’s test
using a statistical package program (SPSS version 17.0). All
P values are two-tailed and P< 0.05 was considered as signiﬁ-
cant for all statistical analysis in this study.
3. Results
3.1. Kidney index
Statistical analysis of kidney indices for comparison between
control, non treated diabetic treated diabetic with biotin mice
groups registered 0.62 in the control group, 0.78 and 0.61
in non treated and treated diabetic groups, respectively
(Table 1) that showed a signiﬁcant increase in the nontreated
diabetic group compared to the control group, a signiﬁcant
decrease in the treated diabetic group compared to the non-
treated group and no difference in kidney index value between
treated diabetic and control groups.
3.2. Renal injury
Glomerular areas of the experimental groups were measured
that showed an increase in glomerular areas in diabetic groups
when compared with the control group, control group regis-
tered (2.9 lm3), whereas, untreated diabetic and treated
diabetic glomerular areas registered (3.3 and 4.3 lm3) respec-
tively (Table 1) that considered a signiﬁcant increase
(P< 0.05) between control and diabetic groups, but there
was an insigniﬁcant increase between untreated and treated
diabetic groups. Glomerular cellularity showed a signiﬁcant
decrease in diabetic groups when compared with the control
group (P< 0.05) that registered (64, 24 and 26 cells/gcs) for
control, untreated diabetic and treated diabetic with biotin,
respectively (Table 1) that showed an insigniﬁcant difference
between untreated and treated diabetic groups.Table 1 Biotin induced changes in kidney index, glomerular
area and glomerular cellularity of STZ-induced diabetes in
mice.
Group Kidney
index (%)
Glomerular
area (lm3)
Glomerular
cellularity (cells/
gcs)
Non-diabetic
(Biotin)
0.62 ± 0.12 2.9 ± 0.723 64 ± 8.7
Diabetic
(Biotin)
0.78 ± 0.2a 3.3 ± 0.285 24 ± 2.3a
Diabetic
(+Biotin)
0.61 ± 0.15b 4.3 ± 0.357 26 ± 1.8a
Values are means ± SD.
a Signiﬁcant against non-diabetic (Biotin) group at P 6 0.05.
b Signiﬁcant against diabetic (Biotin) group at P 6 0.05.3.3. Biochemical analysis
Biochemical analysis of blood sera collected from the three
experimental groups showed normal glucose level in the con-
trol group (104 gm/d1) (Table 2) and a signiﬁcant increase of
blood glucose level (P< 0.05) in untreated and treated dia-
betic groups (333 and 294 gm/d1) respectively, there was a
slight decrease in glucose levels between untreated diabetic
and treated diabetic with biotin groups that considered an
insigniﬁcant decrease. Blood urea nitrogen (BUN) showed a
signiﬁcant increase (P< 0.05) between the control group that
registered normal BUN level (20 mg/dl) and untreated and
treated diabetic groups that registered (36 and 30 mg/dl),
respectively (Table 1), an insigniﬁcant decrease in BUN levels
was registered between untreated and treated diabetic groups.
Diabetic groups (0.6, 0.4 and 0.4), respectively (Table 2) repre-
sented an insigniﬁcant difference among the three experimental
groups.
3.4. Histological and immunohistochemical results
Kidney sections of control mice showed normal histology of
cortex and medulla, cortex section (Fig. S1A) showed normal
glomerulus in Bowman’s capsule surrounded by clear area
called capsular space, macula densa appeared near vascular
pole of the glomerulus surrounded by many sections of proxi-
mal and distal convoluted tubules. Control kidney section
showed a negative response to anti-acrolein immuno-
histochemistry reaction with no brownish immunoprecipitate
(Fig. S1B).
Histological examination of kidney of diabetic mice showed
severe histopathological alterations as: distorted glomeruli sur-
rounded by aggregations of neutrophilic inﬂammatory cells,
giant rounded macrophages among inﬂammatory cells,
increasing of myoﬁbroblast cells, and degeneration of both dis-
tal and proximal convoluted tubule cells. Other evidences of
histopathological damage by diabetes include the increase in
the capsular space around glomeruli due to diminishing of
glomerular size itself, darkly stained lymphocytes appeared
forming lymphocytic inﬁltration and scattered lymphocytes
and neutrophils inﬂammatory cells among tubules besides
accumulation of myoﬁbroblast cells. Dilatation in kidney
blood vessels with erythrocytic congestion surrounded by leu-
kocytic inﬁltration was also seen (Fig. 1A and B). Diabetes
induced moderate to intense acrolein immune-reactivity inTable 2 Biotin induced changes in glucose, blood urea
nitrogen and creatinine in blood of STZ-induced diabetic mice.
Blood glucose
(mg/dl)
BUN
(mg/dl)
Creatinine
(mg/dl)
Non-diabetic
(Biotin)
104 ± 36 20 ± 4 0.6 ± 0.2
Diabetic
(Biotin)
333 ± 46a 36 ± 1a 0.4 ± 0
Diabetic
(+Biotin)
294 ± 97 30 ± 3a,b 0.4 ± 0.03
Values are means ± SD.
a Signiﬁcant against non-diabetic (Biotin) group at P 6 0.05.
b Signiﬁcant against diabetic (Biotin) group at P 6 0.05.
Figure 1 Histopathological alterations in renal tissue of STZ-induced diabetic mice. G: distorted glomeruli, IF: leukocytic inﬂammation,
Mand arrow: giant macrophage (A), BV: congested blood vessels (B). Renal tissue of STZ-induced diabetic mice and treated with biotin.
Sections show improved glomeruli in cortex and more or less healthy cubical cells of convoluted tubules and with healthy medullary rays
(C and D). Sections are stained with hematoxylin and eosin. Scale bar = 50 lm.
Figure 2 Renal tissue of STZ-induced diabetic mice with intense acrolein reddish brown precipitate of avidin–biotin complex in
glomeruli and tubules (arrows) (A). Renal tissue of STZ-induced diabetic mice and treated with biotin showing slight brown precipitate of
acrolein in convoluted tubules (arrows) (B). Sections are stained with ABC immunostain. Scale bar = 50 lm.
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reddish brown precipitate (Fig. 2A).
Kidney sections of diabetic mice treated with 15 mg/kg of
biotin showed less pathological changes compared with dia-
betic group. There was an improvement within glomeruli with
high cellularity appeared in the cortex tissue and most of distal
and proximal tubules showed healthy cubical cells with abun-
dant nuclei (Fig. 1C). Medulla section showed wide dilated
collecting tubules with abundant nuclei, some of tubular cells
showed degenerated cytoplasm and other showed apoptotic
nuclei (Fig. 2B). Treatment with biotin for diabetes mice
reduced acrolein expression in kidneys represented by pale red-
dish brown precipitate (Fig. 2B).
4. Discussion
In the current work, diabetes was induced in laboratory mice
via intraperitoneal injection of (150 mg/kg/bw) streptozotocin.STZ is considered to be toxic to insulin producing beta cells
within pancreas, and thus it is widely used to induce experi-
mental diabetes in laboratory animals (Casey et al., 2004;
Gojo et al., 2007).
Our data showed that STZ-induced diabetic mice showed a
signiﬁcant increase in blood urea and glucose levels, and kid-
ney index between control and diabetic groups, and with
insigniﬁcant changes in serum creatinine and glomerular areas.
Upon biotin administration to diabetic mice, both kidney
index and blood urea nitrogen were signiﬁcantly decreased,
and there were no signiﬁcant changes in blood glucose,
glomerular cellularity and serum creatinine in comparison with
untreated diabetic mice.
Biotin is the cofactor for many enzymes in the body.
Physiologically, biotin is playing a key role in the metabolism
of carbohydrates, lipids, proteins and nucleic acid. It plays an
irreplaceable role in maintaining metabolic dynamic equilib-
rium (Pacheco-Alvarez et al., 2002). Pharmacologically, biotin
568 B.A. Aldahmash et al.can reduce type I diabetes blood sugar levels, improve the
experimental rats glucose tolerance and insulin resistance
(Fernandez-Mejia, 2005). Biotin regulates blood glucose levels
in both hypo- and hyperglycemia. Biotin treatment lower post-
prandial glucose levels, improved glucose tolerance and
enhanced endogenous insulin sensitivity (Reddi et al., 1988).
In addition, biotin enhances insulin biosynthesis and hence
protects b-cell dysfunction induced by glucotoxicity or lipo-
toxicity (Yoshikawa et al., 2002).
Previous studies proved that, diabetes mellitus type I
induces hypertrophic changes within kidneys (Yamamoto
et al., 2001; Romero et al., 2013). In addition, morphometric
analysis of kidney sections revealed that STZ-induced diabetic
mice had an increase in glomerular areas and hypercellularity
(Wada et al., 2001; Chow et al., 2004; Spencer et al., 2004;
Kiran et al., 2012). The present study agreed with previous
studies that untreated and treated diabetic mice groups showed
an increase in glomerular area due to expansion of glomerular
cells, distortion and dilatation in Bowman’s capsules which
lead to an increase in capsular space, but the present study
revealed that early stage of nephrotoxicity in diabetes mice
STZ-induced showed hypocellularity due to degeneration of
glomerular cells.
The present study showed marked pathological changes in
untreated STZ-induced diabetic kidney mice as manifested
by distorted and dilated glomeruli with expanded matrix and
degenerated cells, giant multinucleated macrophages, aggrega-
tions of neutrophils, lymphocytic inﬁltration, accumulation of
myoﬁbroblast like cells and degeneration of tubular cells.
Approximately 30% of insulin-dependent diabetes mellitus
patients suffer from diabetic nephropathy which is considered
to be a life-threatening complication of diabetes mellitus
(Bojestig et al., 1994; Krolewski et al., 1996). Our results are
in agreement with many previous studies that proved these
induced pathological alterations (Zafar et al., 2009; Wada
et al., 2001; Chow et al., 2005) whereas treated diabetic mice
with biotin showed less pathological alterations compared with
the untreated diabetic group manifested by more or less
healthy tubules and improved glomeruli.
Examination of kidney sections incubated with anti-acro-
lein antibodies showed an intense immunoreactivity against
acrolein in renal tissues which indicates the strong oxidative
damage in kidneys of STZ-induced diabetic mice. Upon treat-
ment of diabetic mice with biotin, the immunoreactivity
against acroline was strongly reduced indicating that biotin
reduced oxidative stress in diabetic kidney mice.
Diabetes is usually associated with a status of oxidative
stress represented as decreased GSH levels and increased lipid
peroxidation products (Seghrouchni et al., 2002). STZ injec-
tion causes inﬂammatory cell inﬁltration within the pancreas
followed by the onset of insulin deﬁciency, and activates pro-
tein kinase-C, poly (ADP-ribose) polymerase and NAD(P)H
oxidase, with consequent generation of ROS and advanced
glycation end products resulting in renal damage and
nephropathy (Kolb and Kroneke, 1993; Like and Rossini,
1976; Szabo, 2005; Arora et al., 2009).
There is increasing evidence that aldehydes generated
endogenously during lipid peroxidation contribute to the
pathophysiologic effects associated with oxidative stress in
cells and tissues. A number of reactive lipid aldehydes, such
as 4-hydroxy-2-alkenals and malondialdehyde, have been
implicated as causative agents in cytotoxic processes initiatedby the exposure of biologic systems to oxidizing agents.
Recently, acrolein (CH2‚CHACHO), a ubiquitous pollutant
in the environment, was identiﬁed as a product of lipid perox-
idation reactions. The identiﬁcation of acrolein as an endoge-
nous lipid-derived product suggests an examination of the
possible role of this aldehyde as a mediator of oxidative dam-
age in a variety of human diseases (Uchida, 1999). Lipid per-
oxidation is implicated in the pathogenesis of numerous
diseases; including atherosclerosis, diabetes, cancer, and
rheumatoid arthritis, as well as in drug-associated toxicity,
post is chemic reoxygenation injury, and aging. Lipid peroxi-
dation proceeds by a free-radical chain reaction mechanism
and yields lipid hydroperoxides as major initial reaction prod-
ucts. Subsequently, decomposition of lipid hydroperoxides
generates a number of degradation products that lead to a
wide variety of damaging actions (Esterbauer et al., 1991).
The present study reported that kidneys of untreated diabetic
mice showed intense acrolein gene expression immunoreactiv-
ity as a product of lipid peroxidase that leads to oxidative
stress whereas, kidneys of diabetic mice treated with biotin
showed slight acrolein immunoreactivity indicating that biotin
reduced oxidative stress in diabetic kidney mice.
Although its beneﬁcial effects are largely known, there are
no available data in the literature regarding the protective role
of biotin against organ induced cytotoxicity or its antioxidant
properties. It was found that biotin levels positively correlate
with antioxidant levels as reduced glutathione, glutathione
peroxidase, catalase and superoxide dismutase (Al-Qudah
and Ismail, 2012). Low serum biotin levels initiate a series of
biochemical events that lead potentially to the release of harm-
ful lipid peroxidation by-products. In addition, biotin plays an
important role in the regulation of chromatin structures, gene
expression, and DNA repair (Gravel and Narang, 2005;
Hassan and Zempleni, 2006) that may investigate the obtained
data of low immunoreactivity against acrolein in renal tissues
after biotin treatment of STZ-induced diabetic mice.
In conclusion, biotin is found to reduce STZ-induced dia-
betic associated renal tissue alterations and oxidative damage.
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